WO2004073685A1 - Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor - Google Patents
Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor Download PDFInfo
- Publication number
- WO2004073685A1 WO2004073685A1 PCT/IE2004/000024 IE2004000024W WO2004073685A1 WO 2004073685 A1 WO2004073685 A1 WO 2004073685A1 IE 2004000024 W IE2004000024 W IE 2004000024W WO 2004073685 A1 WO2004073685 A1 WO 2004073685A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dexamethasone
- viscosity increasing
- tablet
- granulation
- starch
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Definitions
- This invention relates to a method for formulating the corticosteriod dexamethasone into a granulation.
- the manufacture of drug formulations for pharmaceutical use can be complex in preparing a single drug formulation or a combination of drugs in a formulation for optimum efficacy. Different drugs can have very different properties and require different handling methods.
- Dexamethasone is a very potent corticosteroid; it has thirty times the anti- inflammatory potency of cortisone (The Pharmacological basis of Therapeutics, Ninth edition, Goodman and Gilman, page 1466). As a result, only a small amount of drug is needed in the oral dosage form (tablet) which is given to the patient. Generally, only 0.25 mg dexamethasone is present in a 300 mg tablet (0.083%). The challenge is to uniformly disperse the small amount of drug in the tablet granulation to provide uniformity of dose in the compressed tablets.
- dexamethasone has been incorporated into the tablet granulation either by direct compression or wet granulation.
- Direct compression techniques use ordered mixing to gradually mix the dexamethasone with increasing amounts of excipient. While a uniform mix may result in the blender, segregation may occur as the granulation is transferred into other containers or while being fed into the tablet press. This "in process" segregation can result in non uniform tablets.
- WO 96/40078A describes dissolving dexamethasone and polyvinyl pryrollidone in ethanol. The solution is added drop-wise to guar gum to form granules.
- JP 11130663 describes suspension of biotin in hydroxy propyl cellulose or hydroxy propyl methylcellulose and water. The suspension is dispersed using a wet granulation technique.
- a process for manufacturing a formulation of dexamethasone comprising preparing a dilute aqueous suspension of dexamethasone, spraying the suspension onto base ingredient (s), and drying the resultant mixture to provide a granulation.
- the dilute aqueous suspension is prepared by mixing the compound with a viscosity increasing excipient.
- the viscosity increasing excipient is selected from any one ore more of starch, pre-gelatinised starch, hydroxypropylmethylcellulose, methycellulose or povidone.
- the viscosity increasing excipient is starch.
- weight ratio of the viscosity increasing excipient to the pharmaceutical com ipound is from 12:1 to 60:1, most preferably approximately 30:1.
- the viscosity increasing excipient is present in an amount of from 0.5% to 5.0% w/w of the tablet formulation.
- the process comprises milling the aqueous mixture of dexamethasone and the viscosity increasing excipient to form a dexamethasone suspension.
- the process may comprise suspending the viscosity increasing excipient in water and subsequently adding the dexamethasone to the suspension to form a mixture.
- the suspension is sprayed onto the base ingredient(s) in a fluidised bed dryer.
- the resulting granulation is compressed into a tablet.
- the pharmaceutical compound is present in the tablet in an amount of from 2 to 0.02% w/w of the formulation, most preferably in an amount of approximately 0.083% w/w.
- the dexamethasone may be in the form of dexamethasone base.
- the invention provides a granulation or powder dosage form whenever manufactured by a process of the invention.
- granulation is taken throughout to include from very fine dusty powders to larger particle sizes such as granules.
- the invention also provides a tablet or tablet dosage form whenever manufactured by a process of the invention.
- the tablet comprises an amount of from 2 to 0.02% w/w of the formulation of dexamethasone and from 0.5% to 5% w/w of the formulation of a viscosity increasing excipient.
- the viscosity increasing excipient is selected from any one or more of starch, pre-gelatinised starch, hydroxypropyl-methylcellulose or povidone, preferably the viscosity increasing excipient is starch.
- the present invention utilizes a viscous aqueous based spray solution to provide a uniform distribution of a small amount of dexamethasone in a large amount of granulation. After the water evaporates, dexamethasone is bound to the granulation, reducing the potential for downstream segregation.
- dexamethasone could be combined with water and a viscosity building excipient and suspended in a spray solution.
- excipients may be used to provide sufficient viscosity to the spray solution.
- suitable excipients include starch, pregelatinised starch, hydroxypropylmethylcellusose, methylcellulose and povidone. The amount required depends on a number of factors such as the time a solution is left standing, and the degree of agitation of the mixer.
- starch was used as the viscosity increasing excipient to make the spray solution comprising dexamethasone.
- a range of concentrations of starch paste were prepared and milled to observe the cut off point for the dexamethasone separating out. The range of 0.5% to 5.0% was investigated. The 0.5% sample showed some settling, but was readily dispersed. Even the 0.5% concentration would be acceptable when it is continuously mixed during spraying.
- dexamethasone is incorporated into a very dilute paste with sufficient viscosity to prevent separation and ensure a uniform, suspended ingredient.
- the spray solution must be sufficiently dilute to be sprayed on the batch.
- the excipients providing viscosity to the aqueous solution act as "glue” and bind the dexamethasone to the granulation after the water evaporates away.
- the resulting granulation is uniform and the dexamethasone is bound to the granulation which minimizes segregation during subsequent product transfer.
- Base ingredients may include any conventionally used carrier ingredient commonly used in the art.
- lactose lactose, microcrystalline cellulose, dibasic calcium phosphate, starch, dextrin, maltodextrin, compressible sugar, dextrose, and calcium sulfate.
- the mixing sequence used for dexamethasone includes preparing the starch paste, adding dexamethasone to a portion of the starch paste to make a slurry (lumps may be present), then milling the slurry once or multiple times until it is a uniform suspension, followed by purging the mill with starch paste to remove residual dexamethasone in the mill. The milled suspension and purge are then added to the spray solution tank for spraying onto the granulation using a Glatt Fluid bed drier.
- the starch is approximately 0.5% to 5.0% weight/weight of the batch.
- the excipient used to provide viscosity to the spray solution is starch, pregelatinized starch, hydroxypropylmethylcellulose, methylcellulose, or povidone.
- composition may be provided in the form of a uniform granulation which may be used a powder dosage form.
- composition may be provided in the form of a uniform granulation which can be compressed into tablets.
- a 540 kg batch of dexamethasone 0.25 mg tablets was prepared according to the following procedure:
- the resulting dexamethasone 0.25 mg tablets are uniform in potency. Content uniformity testing gave an average of 101.2% claim with an RSD of 0.8%.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602004020187T DE602004020187D1 (en) | 2003-02-20 | 2004-02-19 | Process for the preparation of a formulation containing dexamethasone for oral administration |
EP04712644A EP1594471B1 (en) | 2003-02-20 | 2004-02-19 | Process for manufacturing a dexamethasone-containing formulation for oral administration |
US11/207,749 US20060034915A1 (en) | 2003-02-20 | 2005-08-22 | Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44817403P | 2003-02-20 | 2003-02-20 | |
US60/448,174 | 2003-02-20 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/207,749 Continuation US20060034915A1 (en) | 2003-02-20 | 2005-08-22 | Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004073685A1 true WO2004073685A1 (en) | 2004-09-02 |
Family
ID=32908546
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IE2004/000024 WO2004073685A1 (en) | 2003-02-20 | 2004-02-19 | Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060034915A1 (en) |
EP (1) | EP1594471B1 (en) |
AT (1) | ATE426398T1 (en) |
DE (1) | DE602004020187D1 (en) |
WO (1) | WO2004073685A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2455539B (en) * | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
CN105997866B (en) * | 2016-07-13 | 2019-08-20 | 成都明慈医药科技有限公司 | A kind of suspension and preparation method thereof containing dexamethasone |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
WO2020168106A1 (en) | 2019-02-13 | 2020-08-20 | Notable Labs, Inc. | Combinations of agonists of protein kinase c with steroids or retinoic acids for the treatment of cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB970440A (en) * | 1961-08-14 | 1964-09-23 | Merck & Co Inc | Anti-inflammatory compositions comprising steroids and indole derivatives |
US3231468A (en) * | 1962-07-02 | 1966-01-25 | Merck & Co Inc | Dexamethasone-cyproheptadine oral antiflammatory compositions |
WO1998022095A1 (en) * | 1996-11-15 | 1998-05-28 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
WO1998035701A1 (en) * | 1997-02-11 | 1998-08-20 | Theramark Limited | Drug targeting |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2946298A (en) * | 1957-11-13 | 1960-07-26 | Arthur Colton Company | Compression coating tablet press |
NL256065A (en) * | 1959-10-01 | |||
JPS5759803A (en) * | 1980-09-30 | 1982-04-10 | Takeda Chem Ind Ltd | Granule of l-sodium ascorbate, its preparation, and tablet comprising it |
WO1986005124A1 (en) * | 1985-03-01 | 1986-09-12 | Freund Industrial Co., Ltd. | Apparatus for and method of granulating fluidized pulverized material and coating granulated products |
US5686106A (en) * | 1995-05-17 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
IT1303692B1 (en) * | 1998-11-03 | 2001-02-23 | Chiesi Farma Spa | PROCEDURE FOR THE PREPARATION OF SUSPENSIONS OF PARTICLES OF DRUGS TO BE ADMINISTERED BY INHALATION. |
-
2004
- 2004-02-19 AT AT04712644T patent/ATE426398T1/en not_active IP Right Cessation
- 2004-02-19 DE DE602004020187T patent/DE602004020187D1/en not_active Expired - Fee Related
- 2004-02-19 EP EP04712644A patent/EP1594471B1/en not_active Expired - Lifetime
- 2004-02-19 WO PCT/IE2004/000024 patent/WO2004073685A1/en active Application Filing
-
2005
- 2005-08-22 US US11/207,749 patent/US20060034915A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB970440A (en) * | 1961-08-14 | 1964-09-23 | Merck & Co Inc | Anti-inflammatory compositions comprising steroids and indole derivatives |
US3231468A (en) * | 1962-07-02 | 1966-01-25 | Merck & Co Inc | Dexamethasone-cyproheptadine oral antiflammatory compositions |
WO1998022095A1 (en) * | 1996-11-15 | 1998-05-28 | The Procter & Gamble Company | Pharmaceutical dosage form for colonic delivery |
WO1998035701A1 (en) * | 1997-02-11 | 1998-08-20 | Theramark Limited | Drug targeting |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8101741B2 (en) | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US8188263B2 (en) | 2005-11-02 | 2012-05-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US8513403B2 (en) | 2005-11-02 | 2013-08-20 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US9074208B2 (en) | 2005-11-02 | 2015-07-07 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US7915399B2 (en) | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1594471B1 (en) | 2009-03-25 |
ATE426398T1 (en) | 2009-04-15 |
DE602004020187D1 (en) | 2009-05-07 |
US20060034915A1 (en) | 2006-02-16 |
EP1594471A1 (en) | 2005-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2166936C2 (en) | Method of preparing dosing units by wet granulation method | |
NO305055B1 (en) | Pharmaceuticals Surface Dry Composition, Pharmaceuticals Surface Dispensing Unit, Method of Preparation thereof, and Method of Preparation of Tablets | |
US20060034915A1 (en) | Dexamethasone-containing formulations for oral administration as well the process for manufacturing required therefor | |
NO176125B (en) | Process for preparing granules for controlled release oral multiparticulate compositions | |
KR100580855B1 (en) | Stabilized tibolone compositions | |
CN110496122A (en) | Pharmaceutical composition comprising Fimasartan and Hydrochioro | |
JPH05320045A (en) | Spray drying method for manufacturing medicine powder composition being compressable directly to tablet | |
JPH0774153B2 (en) | Loxoprofen / sodium-containing preparation | |
Kukkar et al. | Mixing and formulation of low dose drugs: underlying problems and solutions | |
NZ547527A (en) | Low-dose tablets having a network of polymers | |
CA2275626C (en) | Homogeneous preformulations containing high concentrations of steroids, for producing low-dose solid and semi-solid pharmaceutical preparations | |
EP2072041B1 (en) | Method for preparing film-coated tablets containing drospirenone as active agent | |
WO1995017168A1 (en) | Method for preparing low dose pharmaceutical products | |
CN105055350A (en) | Preparation method of proton pump inhibitor-containing tablet | |
IE20040104A1 (en) | A process for manufacturing a formulation of dexamethasone | |
CN103181905B (en) | A kind of technique preparing pramipexole hydrochloride tablet | |
EP0735862B1 (en) | Method for dry blend compression of medicaments | |
NO780799L (en) | PROCEDURE FOR PREPARING A SOLID STEROID PREPARATION | |
CZ24798A3 (en) | Process for preparing solid dosing forms with a very low dosage of medicament, pharmaceutical preparation and use | |
CZ295584B6 (en) | Pharmaceutical composition containing platinum complex as active component and process for preparing such composition | |
MXPA98000809A (en) | Procedure to prepare forms of solid doses of very low dose of farm | |
CN110575441A (en) | Preparation method of valsartan tablets | |
CN115671062A (en) | Finasteride tablet with raw material granularity controlled and production process thereof | |
WO2011008674A1 (en) | Material and process for incorporation of low dosage active pharmaceutical ingredients and use thereof | |
CN117482057A (en) | Stable granisetron hydrochloride tablet and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 11207749 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004712644 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004712644 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11207749 Country of ref document: US |